Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will report first-quarter 2026 financial results on May 6, 2026 after market close. A live webcast with senior management will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and corporate progress.

The live webcast and an archived replay (available for at least 14 days) can be accessed via the company's investor events and presentations page.

News Market Reaction – RVMD

+2.54%

+2.54% Session close to close

In the Apr 30 session, RVMD gained 2.54%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the date and time for RVMD’s Q1 2026 results and webcast, continuing its patt...

Analysis

This announcement sets the date and time for RVMD’s Q1 2026 results and webcast, continuing its pattern of pre-announcing earnings with a 4:30 p.m. ET call and a replay available for at least 14 days. In context, it follows a series of notable clinical milestones and large capital raises in April 2026. Investors may watch how upcoming results align with the company’s recent trial progress and financing activity, as well as any updated guidance or pipeline commentary.

Key Figures

Q1 2026 report date: May 6, 2026 Earnings webcast time: 4:30 p.m. ET Replay availability: 14 days

3 metrics

Q1 2026 report date May 6, 2026 Scheduled financial results release after market close

Earnings webcast time 4:30 p.m. ET Start time for Q1 2026 results webcast

Replay availability 14 days Webcast replay duration on company website

Previous Earnings date Reports

1 past event · Latest: Feb 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 18	Earnings date announcement	Neutral	+3.0%	Scheduled Q4 and full-year 2025 results with webcast and replay details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history shows prior earnings-date scheduling news coincided with a modest positive move.

Recent Company History

Recent RVMD news has focused on substantial clinical and financing milestones. In April 2026, the company announced multiple positive daraxonrasib trial updates and a large upsized equity and convertible note offering. Against this backdrop, today’s announcement simply sets the timing for Q1 2026 results and a webcast, similar in structure to the prior Feb 25, 2026 earnings-date notice, which preceded a 2.96% positive price reaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When will Revolution Medicines (RVMD) report Q1 2026 results and what time is the webcast?

Revolution Medicines will report Q1 2026 results on May 6, 2026 after market close. According to the company, the management webcast begins at 4:30 p.m. ET / 1:30 p.m. PT to discuss the quarter and corporate progress.

How can investors access the Revolution Medicines (RVMD) May 6, 2026 webcast and replay?

Investors can access the live webcast and replay via the company's investor events page. According to the company, the webcast is at https://ir.revmed.com/events-and-presentations and a replay will be available for at least 14 days.

Who will present Revolution Medicines' Q1 2026 results on May 6, 2026?

Members of Revolution Medicines' senior management team will host the webcast. According to the company, senior management will discuss the financial results for the quarter and provide an update on corporate progress during the session.

Will the Revolution Medicines (RVMD) webcast include corporate progress updates beyond financial results?

Yes, the webcast will cover both results and corporate progress. According to the company, senior management will discuss the quarter's financial results and provide an update on corporate development and programs during the May 6 webcast.